RS53149B - Antagonisti receptora za cgrp - Google Patents

Antagonisti receptora za cgrp

Info

Publication number
RS53149B
RS53149B RS20140035A RSP20140035A RS53149B RS 53149 B RS53149 B RS 53149B RS 20140035 A RS20140035 A RS 20140035A RS P20140035 A RSP20140035 A RS P20140035A RS 53149 B RS53149 B RS 53149B
Authority
RS
Serbia
Prior art keywords
hydrogen
pyridin
hydroxy
difluorophenyl
oxo
Prior art date
Application number
RS20140035A
Other languages
English (en)
Serbian (sr)
Inventor
Guanglin Luo
Gene M. Dubowchik
John E. Macor
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53149(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of RS53149B publication Critical patent/RS53149B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20140035A 2009-10-14 2010-10-13 Antagonisti receptora za cgrp RS53149B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25147709P 2009-10-14 2009-10-14
PCT/US2010/052433 WO2011046997A1 (en) 2009-10-14 2010-10-13 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
RS53149B true RS53149B (sr) 2014-06-30

Family

ID=43242489

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140035A RS53149B (sr) 2009-10-14 2010-10-13 Antagonisti receptora za cgrp

Country Status (35)

Country Link
US (2) US8314117B2 (enExample)
EP (1) EP2488512B1 (enExample)
JP (3) JP5836279B2 (enExample)
KR (3) KR101875353B1 (enExample)
CN (1) CN102656159B (enExample)
AR (2) AR078638A1 (enExample)
AU (1) AU2010306954B2 (enExample)
BR (1) BR112012008828B1 (enExample)
CA (2) CA2968176C (enExample)
CL (1) CL2012000925A1 (enExample)
CO (1) CO6460732A2 (enExample)
CY (1) CY2022023I2 (enExample)
DK (1) DK2488512T3 (enExample)
EA (1) EA020409B1 (enExample)
ES (1) ES2441192T3 (enExample)
FR (1) FR22C1044I2 (enExample)
HR (1) HRP20140111T1 (enExample)
HU (1) HUS2200033I1 (enExample)
IL (1) IL219120A (enExample)
LT (1) LTC2488512I2 (enExample)
LU (1) LUC00272I2 (enExample)
MX (1) MX2012004182A (enExample)
NL (1) NL301187I2 (enExample)
NO (1) NO2022033I1 (enExample)
NZ (1) NZ599281A (enExample)
PE (1) PE20121137A1 (enExample)
PL (1) PL2488512T3 (enExample)
PT (1) PT2488512E (enExample)
RS (1) RS53149B (enExample)
SI (1) SI2488512T1 (enExample)
SM (1) SMT201400019B (enExample)
TN (1) TN2012000139A1 (enExample)
TW (1) TWI465448B (enExample)
WO (1) WO2011046997A1 (enExample)
ZA (1) ZA201203452B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) * 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
RS56556B1 (sr) * 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so
WO2013169563A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TW201718574A (zh) * 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
DK4088720T3 (da) 2018-03-25 2025-09-29 Pfizer Ireland Pharmaceuticals Unlimited Company Rimegepant til cgrp-relaterede lidelser
CN114805206B (zh) * 2021-01-27 2025-01-14 奥锐特药业(天津)有限公司 高光学纯度瑞美吉泮中间体的工业化制备方法
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び/又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
CN116478211B (zh) * 2022-04-19 2023-10-24 石家庄迪斯凯威医药科技有限公司 一种新型cgrp受体拮抗剂及其用途
CN115060824B (zh) * 2022-06-14 2024-03-12 浙江宏元药业股份有限公司 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法
CN117466893A (zh) * 2022-07-29 2024-01-30 熙源安健医药(上海)有限公司 吡啶并环庚烷类衍生物及其制备方法和用途
CN115677694A (zh) * 2022-11-30 2023-02-03 南通常佑药业科技有限公司 一种瑞美吉泮的合成方法
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
CN116768938B (zh) * 2023-05-17 2025-11-11 南京艾德凯腾生物医药有限责任公司 一种铁催化剂及瑞美吉泮中间体的制备方法
CN119661518A (zh) * 2023-09-21 2025-03-21 成都康弘药业集团股份有限公司 一种治疗cgrp相关障碍的小分子药物
CN117486798B (zh) * 2023-12-21 2025-02-07 南京威凯尔生物医药科技有限公司 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor
CN119707808B (zh) * 2024-12-23 2025-12-05 上海彩迩文生化科技有限公司 一种制备cgrp受体拮抗剂中间体的方法
CN121949205A (zh) * 2025-04-15 2026-05-01 常州制药厂有限公司 一种瑞美吉泮中间体及其制备方法
CN122079891B (zh) * 2026-04-22 2026-08-07 烟台大学 Forsyqinlingine C衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7855294B2 (en) 2004-03-05 2010-12-21 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
US20060084708A1 (en) 2004-10-14 2006-04-20 Bayer Materialscience Llc Rigid foams with good insulation properties and a process for the production of such foams
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2007238894A1 (en) 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists

Also Published As

Publication number Publication date
DK2488512T3 (en) 2014-02-24
JP2015163625A (ja) 2015-09-10
HRP20140111T1 (hr) 2014-03-14
CA2968176A1 (en) 2011-04-21
CO6460732A2 (es) 2012-06-15
JP2017125054A (ja) 2017-07-20
JP5836279B2 (ja) 2015-12-24
KR20120087940A (ko) 2012-08-07
JP6258537B2 (ja) 2018-01-10
US20130053570A1 (en) 2013-02-28
TWI465448B (zh) 2014-12-21
IL219120A (en) 2016-12-29
US8314117B2 (en) 2012-11-20
AU2010306954B2 (en) 2016-05-26
HUS2200033I1 (hu) 2022-08-28
EP2488512B1 (en) 2013-11-27
KR101990755B1 (ko) 2019-06-18
PL2488512T3 (pl) 2014-04-30
WO2011046997A1 (en) 2011-04-21
CA2777518C (en) 2017-07-04
SMT201400019B (it) 2014-05-07
PT2488512E (pt) 2014-02-24
ZA201203452B (en) 2014-10-29
CA2968176C (en) 2019-11-26
KR20170081737A (ko) 2017-07-12
EA020409B1 (ru) 2014-10-30
BR112012008828B1 (pt) 2021-11-23
EA201270561A1 (ru) 2012-12-28
PE20121137A1 (es) 2012-08-30
EP2488512A1 (en) 2012-08-22
KR20180080343A (ko) 2018-07-11
LTPA2022516I1 (enExample) 2022-08-25
CL2012000925A1 (es) 2012-08-31
KR101755742B1 (ko) 2017-07-07
US20110251223A1 (en) 2011-10-13
AU2010306954A1 (en) 2012-05-03
AR110069A2 (es) 2019-02-20
NO2022033I1 (no) 2022-07-22
NZ599281A (en) 2013-01-25
SI2488512T1 (sl) 2014-02-28
CN102656159B (zh) 2015-07-01
BR112012008828A2 (pt) 2020-09-15
NL301187I2 (nl) 2022-08-04
IL219120A0 (en) 2012-06-28
LUC00272I2 (enExample) 2025-05-12
MX2012004182A (es) 2012-05-29
CY2022023I1 (el) 2023-01-05
KR101875353B1 (ko) 2018-07-05
CN102656159A (zh) 2012-09-05
FR22C1044I2 (fr) 2023-11-17
TW201118096A (en) 2011-06-01
CY2022023I2 (el) 2023-01-05
LTC2488512I2 (enExample) 2025-03-10
AR078638A1 (es) 2011-11-23
JP2013508281A (ja) 2013-03-07
TN2012000139A1 (en) 2013-09-19
HK1169390A1 (en) 2013-01-25
JP6109874B2 (ja) 2017-04-05
FR22C1044I1 (fr) 2022-09-30
CA2777518A1 (en) 2011-04-21
ES2441192T3 (es) 2014-02-03

Similar Documents

Publication Publication Date Title
JP6258537B2 (ja) Cgrp受容体アンタゴニスト
ES2604827T3 (es) Antagonistas del receptor de piperidinona carboxamida azaindano CGRP
US8044043B2 (en) CGRP receptor antagonists
CA2778886C (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2091328B1 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US20230027198A1 (en) Inhibitors of enl/af9 yeats
TW202345797A (zh) 作為ikzf2降解劑之含雙環雜芳基化合物
US8143403B2 (en) CGRP receptor antagonists
MX2008013760A (es) Compuestos restringidos como antagonistas del receptor del peptido relacionado con el gen de calcitonica (cgrp).
HK1169390B (en) Cgrp receptor antagonists
JP2025541798A (ja) Ccr6阻害剤としてのスルホニル誘導体